Axsome Therapeutics AXSM EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's EPS (basic)?
- Axsome Therapeutics (AXSM) reported EPS (basic) of -$1.26 in Q1 2026.
- How has Axsome Therapeutics's EPS (basic) changed year-over-year?
- Axsome Therapeutics's EPS (basic) decreased by 3.3% year-over-year, from -$1.22 to -$1.26.
- What is the long-term trend for Axsome Therapeutics's EPS (basic)?
- Over 4 years (2021 to 2025), Axsome Therapeutics's EPS (basic) has grown at a 1.5% compound annual growth rate (CAGR), from -$3.47 to -$3.68.
- What does EPS (basic) mean?
- The portion of profit allocated to each share of common stock.
- How do you interpret EPS (basic)?
- Higher values indicate better earnings performance per share, while negative values reflect a loss per share.
- How does EPS (basic) compare across companies?
- Standard metric for equity valuation; widely used by investors to compare profitability across companies of different sizes.